MENU
BBH
ETF ticker: NASDAQ
PRICE
CHANGE
NET ASSETS

BBH stock forecast, quote, news & analysis

The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® U... Show more

Category: #Health
BBH
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for BBH with price predictions
Sep 11, 2026

BBH in upward trend: price may ascend as a result of having broken its lower Bollinger Band on September 08, 2026

BBH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 38 of 44 cases where BBH's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +1.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where BBH advanced for three days, in 244 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

The Aroon Indicator entered an Uptrend today. In 191 of 242 cases where BBH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.

Bearish Trend Analysis

The 10-day RSI Indicator for BBH moved out of overbought territory on August 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 22 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 73%.

The Momentum Indicator moved below the 0 level on September 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BBH as a result. In 80 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.

The Moving Average Convergence Divergence Histogram (MACD) for BBH turned negative on September 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In 44 of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BBH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), IQVIA Holdings (NYSE:IQV), Biogen (NASDAQ:BIIB), Illumina (NASDAQ:ILMN), Incyte Corp (NASDAQ:INCY), Exact Sciences Corp (NASDAQ:EXAS), Intra-Cellular Therapies (NASDAQ:ITCI).

Industry description

The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® U.S. Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

Market Cap

The average market capitalization across the VanEck Biotech ETF ETF is 45.41B. The market cap for tickers in the group ranges from 2.16B to 204.01B. AMGN holds the highest valuation in this group at 204.01B. The lowest valued company is SRPT at 2.16B.

High and low price notable news

The average weekly price growth across all stocks in the VanEck Biotech ETF ETF was -5%. For the same ETF, the average monthly price growth was 4%, and the average quarterly price growth was 23%. ICLR experienced the highest price growth at 3%, while AMGN experienced the biggest fall at -14%.

Volume

The average weekly volume growth across all stocks in the VanEck Biotech ETF ETF was 8%. For the same stocks of the ETF, the average monthly volume growth was 10% and the average quarterly volume growth was -32%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 62
P/E Growth Rating: 47
Price Growth Rating: 38
SMR Rating: 68
Profit Risk Rating: 70
Seasonality Score: -17 (-100 ... +100)
View a ticker or compare two or three
BBH
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Details
Category
Health
Address
335 Madison Ave.19th FloorNew York
Phone
888-658-8287
Web
www.marketvectorsetfs.com